Guardant Health’s Strong 2024 Growth and 2025 Outlook

Guardant Health ( (GH) ) has released its Q4 earnings. Here is a breakdown of the information Guardant Health presented to its investors.

Guardant Health, Inc., a precision oncology company, specializes in advanced blood and tissue tests to enhance cancer patient care and accelerate new cancer therapies. The company recently announced its financial results for the fourth quarter and full year of 2024, highlighting significant revenue growth and strategic advancements.

In 2024, Guardant Health achieved a 31% increase in total revenue, reaching $739 million, driven by a strong performance in oncology clinical tests and biopharma tests. The fourth quarter alone saw a revenue increase of 30% compared to the previous year. Key accomplishments include obtaining Medicare coverage for their Guardant Reveal platform for colorectal cancer surveillance and strategic collaborations with entities like ConcertAI and Boehringer Ingelheim.

The company’s precision oncology revenue grew by 34% year-over-year, supported by increased clinical test volumes and improved reimbursement rates. Despite the net loss of $436.4 million in 2024, this marked an improvement compared to the prior year, primarily due to non-recurring legal expenses recorded in 2023. The company also engaged in strategic financial moves, such as a convertible debt exchange, to extend debt maturity.

Looking ahead, Guardant Health projects its 2025 revenue to be between $850 million and $860 million, representing a 15% to 16% growth. The company anticipates continued acceleration in oncology clinical volumes and expects to reach free cash flow breakeven, excluding its screening business, by the fourth quarter of 2025. Guardant Health remains focused on expanding its impact in cancer detection and treatment through its innovative platforms.